Otsuka (OTCMKTS:OTSKY) Sees Large Volume Increase – Here’s What Happened

Shares of Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw strong trading volume on Wednesday . 35,632 shares traded hands during trading, a decline of 12% from the previous session’s volume of 40,304 shares.The stock last traded at $33.69 and had previously closed at $33.88.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Otsuka Stock Up 0.6%

The stock’s fifty day simple moving average is $34.45 and its 200-day simple moving average is $33.11. The stock has a market cap of $36.45 billion and a P/E ratio of 14.32. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, research analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current fiscal year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.